

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 31/55, C07D 487/12</b>		(11) International Publication Number: <b>WO 99/07380</b>
<b>A1</b>		(43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: <b>PCT/US98/16707</b>		(81) Designated States: CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
(22) International Filing Date: 11 August 1998 (11.08.98)		
(30) Priority Data: 60/055,190 11 August 1997 (11.08.97) <b>US</b>		
(71) Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. [US/US]; 900 Ridgebury Road, Ridgefield, CT 06877 (US).		
(72) Inventors: PROUDFOOT, John, R.; 40 Currituck Road, Newtown, CT 06470 (US). HARGRAVE, Karl; 4 Edna Court, Brookfield, CT 06804 (US).		
(74) Agents: RAYMOND, Robert et al.; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 (US).		
(54) Title: 5,11-DIHYDRO-6H-DIPYRIDO[3,2-b:2',3'-e] AZEPIN-6-ONES AND THEIR USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION		
(57) Abstract  Disclosed are novel 5,11-dihydro-6H-dipyridol[3,2-b:2',3'-e]azepine-6-ones. These are useful in the prevention or treatment of HIV infection.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**5,11-DIHYDRO-6H-DIPYRIDO[3,2-*b*:2',3'-*e*]AZEPINE-6-ONES**  
**AND THEIR USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION**

**Field of the Invention**

The invention relates to novel 5,11-dihydro-6H-dipyrido[3,2-*b*:2',3'-*e*]azepine-6-ones and pharmaceutically acceptable salts thereof, methods for preparing these compounds, the use of these compounds either alone or in combination with other anti-virals, immunomodulators, antibiotics, anti-infectives, or vaccines in the prevention or treatment of HIV infection, and to pharmaceutical compositions containing these compounds.

**Background of the Invention**

The human disease, Acquired Immune Deficiency Syndrome (AIDS), is caused by the Human Immunodeficiency Virus (HIV), particularly the strain known as HIV-1.

Like other viruses, HIV-1 cannot replicate without commandeering the biosynthetic apparatus of the host cell it infects. It causes this apparatus to produce the structural proteins which make up the viral progeny. These proteins are coded for by the genetic material contained within the infecting virus particle, or virion. Being a retrovirus, however, the genetic material of HIV is RNA, not DNA as in the host cell's genome. Accordingly, the viral RNA must first be converted into DNA, and then integrated into the host cell's genome, in order for the host cell to produce the required viral proteins. The conversion of the RNA to DNA is accomplished through the use of the enzyme reverse transcriptase (RT), which is included within the infecting virion along with the RNA. Reverse transcriptase has three known enzymatic functions; it acts as an RNA-dependent DNA polymerase, as a ribonuclease, and as a DNA-dependent DNA polymerase. Acting first as an RNA-dependent DNA polymerase, RT makes a single-stranded DNA copy of the viral RNA. Acting as a ribonuclease, RT frees the DNA just produced from the original viral RNA and destroys the original RNA. Finally, acting as a DNA-dependent DNA polymerase, RT makes a second, complementary DNA

strand, using the first DNA strand as a template. The two strands form double-stranded DNA, which is integrated into the host cell's genome by another enzyme called integrase.

Compounds which inhibit the enzymatic functions of HIV-1 reverse transcriptase will inhibit replication of HIV-1 in infected cells.

A number of compounds that inhibit the enzymatic functions of HIV-1 reverse transcriptase are known. One class of known HIV-1 RT inhibitors is the nucleoside analogs. This class includes 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddI), and 2',3'-dideoxycytidine (ddC). Another class is the non-nucleoside analogs. This class includes, *inter alia*, nevirapine, which is 11-cyclopropyl-5,11-dihydro-4-methyl-6*H*-dipyrido[3,2-*b*:2',3'-*e*][1,4]-diazepin-6-one. Nevirapine and other particularly relevant compounds of the non-nucleoside class are described in U.S. Patent 5,366,972; by Hargrave et al., "Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones", *J. Med. Chem.*, **34**, 2231 (1991); and by Proudfoot et al., "Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones are Potent Inhibitors of both Wild Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes". *J. Med. Chem.*, **38**, 4830-4838 (1995).

#### Object of the Invention

As with any anti-viral therapy, use of RT inhibitors in the treatment of HIV-1 infection tends to produce virus which is less sensitive to the given drug. Resistance (reduced sensitivity) to these drugs is the result of mutations which occur in the reverse transcriptase segment of the *pol* gene.

The object of the present invention is to provide improved, non-nucleoside inhibitors of HIV-1 RT which are more potent against mutant strains of HIV-1 than the known compounds of this class.


The compounds of the present invention satisfy this object in that they are highly potent against not only the wild-type (non-mutated) virus RT enzyme, but are also effective against the Y181C mutant [in which the tyrosine (Y) at codon 181 has been mutated to a cysteine (C) residue] which has been the most commonly observed mutant in clinical studies following therapy with many non-nucleoside reverse transcriptase inhibitors.

#### Summary of the Invention

A first aspect of the invention comprises novel 5,11-dihydro-6*H*-dipyrido[3,2-*b*:2',3'-*e*]azepine-6-ones. These possess inhibitory activity against both wild-type and mutant HIV-1 RT. A second aspect of the invention comprises methods for making these novel compounds. A third aspect of the invention is a method for inhibiting replication of HIV-1 in a human host infected by HIV-1. A fourth aspect of the invention is a method for preventing or treating HIV-1 infection which comprises administering, to a human being exposed to or infected by HIV-1, a prophylactically or therapeutically effective amount of one of the above-mentioned novel compounds, either alone or in combination with other anti-viral agents, immunomodulators, antibiotics, anti-infectives, or vaccines. A final aspect of the invention comprises pharmaceutical compositions suitable for the prevention or treatment of HIV-1 infection comprising the above-mentioned compounds.

Description of the Invention

In one of its composition of matter aspects, the invention comprises 5,11-dihydro-6*H*-dipyrido[3,2-*b*:2',3'-*e*]azepine-6-ones of formula 1



wherein;

X is an oxygen atom or nothing;

R<sup>1</sup> is hydrogen, alkyl of 1 to 4 carbon atoms, fluoroalkyl of 1 to 4 carbon atoms and 1 to 3 fluorine atoms, cycloalkyl of 3 to 6 carbon atoms, alkylthio of 1 to 2 carbon atoms, alkyloxy of 1 to 2 carbon atoms, oxetanyl, thietanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, alkenylmethyl or alkynylmethyl of 3 to 4 carbon atoms, alkyloxyalkyl or alkylthioalkyl of 2 to 3 carbon atoms, alkanoyl or alkyl(thiocarbonyl) of 2 to 5 carbon atoms, or cyanoalkyl of 2 to 3 carbon atoms;

R<sup>2</sup> is hydrogen, methyl or ethyl;

R<sup>3</sup> is a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 6 carbon atoms, trihalomethyl, hydroxyalkyl of 1 to 6 carbon atoms, alkyloxy or alkylthio of 2 to 6 carbon atoms, alkyloxyalkyl or alkylthioalkyl of 2 to 6 carbon atoms, pyrrolidinyl, pyrrolinyl, piperidinyl, mono- or di-alkylamino wherein each alkyl moiety contains 1 to 3 carbon atoms, halogen, cyano, nitro, or carboxyl, aryl (wherein aryl is phenyl, pyridinyl, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,

thiazolyl or isothiazolyl) which is either unsubstituted or substituted by hydroxyl, amino, halogen, alkyl or alkyloxy of 1 to 3 carbon atoms.

A subgeneric aspect of the invention comprises compounds of formula 1, wherein:

X is nothing;

R<sup>1</sup> is hydrogen, alkyl of 1 to 3 carbon atoms, cycloalkyl of 3 to 4 carbon atoms, alkylthio of 1 to 2 carbon atoms;

R<sup>2</sup> is hydrogen, methyl or ethyl;

R<sup>3</sup> is a hydrogen atom, methyl, trihalomethyl, alkyloxy or alkylthio of 1 to 2 carbon atoms, pyrrolidinyl, pyrrolinyl, piperidinyl, di-alkylamino wherein each alkyl moiety contains 1 to 2 carbon atoms, halogen, cyano, aryl (wherein aryl is phenyl, pyridinyl, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl or isothiazolyl) which is either unsubstituted or substituted by hydroxyl, amino, halogen, alkyl or alkyloxy of 1 to 3 carbon atoms.

A particular subgeneric aspect of the invention comprises compounds of formula 1, wherein:

X is nothing;

R<sup>1</sup> is ethyl, cyclopropyl, or methylthio;

R<sup>2</sup> is hydrogen;

R<sup>3</sup> is hydrogen, chloro, methoxy or 4-pyrazolyl.

Preferred compounds of formula 1 are:


5-methyl-11-ethyl-2-(4-pyrazolyl)-5,11-dihydro-6*H*-dipyrido[3,2-*b*:2',3'-*e*]azepine;

5-methyl-11-ethyl-2-methoxy-5,11-dihydro-6*H*-dipyrido[3,2-*b*:2',3'-*e*]azepine.

Synthesis Of Compounds Of Formula 1 And Their Salts.


The compounds of Formula 1 and their salts can be prepared by known methods, or obvious modifications thereof, in accordance with the general synthetic scheme shown below.






Method A

Compounds of formula 1




1

wherein  $R^1$  through  $R^3$  are as defined above, and  $R^1$  and  $R^2$  are not both hydrogen may be obtained from a compound of formula 1 wherein one of  $R^1$  or  $R^2$  is hydrogen by conversion to the corresponding, wherein  $M^+$  represents an alkali metal such as lithium, sodium or potassium, in an inert solvent such as TETRAHYDROFURAN, DMSO or the like, and subsequently reacting it with a compound of formula  $R^2-X$  wherein  $R^2$  is as previously defined, and X is the radical of a reactive ester, a halogen atom, methanesulfonyloxy, trifluoromethanesulfonyloxy or an aromatic sulfonyloxy group.




## Compounds of formula 1




1

wherein  $R^1$  through  $R^3$  are as defined above, may be obtained from a compound of formula 2 by deoxygenation with reagents such as phosphorus trichloride in an inert solvent such as chloroform, or Lawessons reagent in an inert solvent such as toluene at some temperature between room temperature and the boiling point of the solvent.



2


## Compounds of formula 2




3

wherein  $R^1$  through  $R^3$  are as defined above, may be obtained from a compound of formula 3 wherein  $R^1$  through  $R^3$  are as defined above, and  $R^4$  is a chloro or bromo substituent, by conversion to the corresponding metal salt 4, wherein  $M^+$  represents an alkali metal such as lithium, sodium or potassium, in an inert solvent such as TETRAHYDROFURAN, DMSO or

the like, and subsequently reacting the cyclized intermediate **5** with a compound of formula  $R^1-X$  wherein  $R^1$  is as previously defined and  $X$  is the radical of a reactive ester, a halogen atom, methanesulfonyloxy, trifluoromethanesulfonyloxy or an aromatic sulfonyloxy group, or by reacting **5** with a compound of formula  $R^1-S-S-R^1$  wherein  $R^1$  is as previously defined.



Compounds of formula **3**



wherein  $R^3$  and  $R^4$  are as described above may be obtained from a compound of formula **7** by reaction with hydrogen peroxide in acetic acid at the boiling point of the solvent.

2-Chloronicotinic acid amides of general formula 7 can be obtained by condensation of 2-methylnicotinic acid chloride with an appropriately substituted 3-amino-2-halopyridine, under well known reaction conditions.

All the other starting materials needed to prepare compounds of the formula 1 are known from the literature, or may be purchased, or may be obtained by procedures known from the literature.

#### Formation Of Salts And Other Derivatives

Compounds of formula 1 may, if desired, be converted into their non-toxic, pharmaceutically acceptable addition salts by conventional methods; for example, by dissolving a compound of formula 1 in a suitable solvent and treating the solution with one or more molar equivalents of the desired acid or base, as appropriate. The invention also comprises such salts.

Examples of inorganic and organic acids which may form nontoxic, pharmaceutically acceptable acid addition salts with a compound of the formula 1 are the following: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, methanesulfonic acid, tartaric acid, fumaric acid, acetic acid, and the like. Examples of inorganic and organic bases which may form nontoxic, pharmaceutically acceptable basic addition salts with a compound of the formula 1 are the following: sodium hydroxide, potassium hydroxide, magnesium hydroxide, ammonia, tromethamine, and the like. Compounds of formula 1 may form addition salts with one molar equivalent of the acid or base, as appropriate.

It will be obvious to those skilled in the art that in some instances the reactions described in Methods A to H cannot be effected in the presence of reactive intermediates incompatible with the reaction conditions. In such cases, the reactive substituent must first be derivatized

via known per se methods to contain a suitable protective group, which can then be subsequently removed.

### Biological Properties

The above described compounds of formula 1 possess inhibitory activity against HIV-1 reverse transcriptase. By inhibiting HIV-1 reverse transcriptase, they ultimately inhibit or suppress the ability of the virus to integrate its genome into the genome of potential host cells, which, in turn, inhibits or suppresses viral replication. When administered in suitable dosage forms, alone or in combination with other anti-virals, immunomodulators, antibiotics, anti-infectives, or vaccines, they are, thus, useful in the prevention or treatment of HIV-1 infection. Another aspect of the invention, therefore, is a method for preventing or treating HIV-1 infection which comprises administering to a human being, exposed to or infected by HIV-1, a prophylactically or therapeutically effective amount of a novel compound of formula 1, as described above.

As the term is used herein, infection by HIV-1 constitutes the replication of HIV-1 in a human host.

As the term is used herein, the treatment of HIV-1 infection comprises the partial or total inhibition or suppression of replication of HIV-1 in a human host in whom replication of the virus has already begun to take place.

As the term is used herein, the prevention of HIV-1 infection comprises the complete prevention of the establishment of viral replication in a human host who has been exposed to HIV-1 but in whom replication of the virus has not yet begun to take place.

The compounds of the present invention are effective agents for the treatment of HIV-1 infection by virtue of their ability to partially or totally inhibit or suppress replication of HIV-1 in an infected human host.

When used to treat HIV-1 infection, the compounds of the present invention can be administered either before or after the onset of clinical manifestations of HIV-1 infection, such as ARC or AIDS.

The compounds of the present invention are effective for the prevention of HIV-1 infection in humans, by virtue of their ability to prevent the establishment of viral replication in a human host who has been exposed to HIV-1 but in whom replication of the virus has not yet begun to take place.

The compounds of formula **1** may be administered in single or divided doses by the oral, parenteral or topical routes. A suitable oral dosage for a compound of formula **1** would be in the range of about 100 mg to 3 g per day. A preferred oral dosage for a compound of formula **1** would be the maximum tolerated dose, which would typically be in the range of between about 200 mg and 2 g per day. In parenteral formulations, a suitable dosage unit may contain from 0.1 to 250 mg of said compounds, preferably 1 mg to 200 mg, whereas for topical administration, formulations containing 0.01 to 1% active ingredient are preferred. It should be understood, however, that the dosage administration from patient to patient will vary and the dosage for any particular patient will depend upon the clinician's judgement, who will use as criteria for fixing a proper dosage the size and condition of the patient as well as the patient's response to the drug.

When the compounds of the present invention are to be administered by the oral route, they may be administered as medicaments in the form of pharmaceutical preparations which contain them in association with a compatible pharmaceutical carrier material. Such carrier

material can be an inert organic or inorganic carrier material suitable for oral administration. Examples of such carrier materials are water, gelatin, talc, starch, magnesium stearate, gum arabic, vegetable oils, polyalkylene-glycols, petroleum jelly and the like.

The pharmaceutical preparations can be prepared in a conventional manner and finished dosage forms can be solid dosage forms, for example, tablets, dragees, capsules, and the like, or liquid dosage forms, for example solutions, suspensions, emulsions and the like. The pharmaceutical preparations may be subjected to conventional pharmaceutical operations such as sterilization. Further, the pharmaceutical preparations may contain conventional adjuvants such as preservatives, stabilizers, emulsifiers, flavor-improvers, wetting agents, buffers, salts for varying the osmotic pressure and the like. Solid carrier material which can be used include, for example, starch, lactose, mannitol, methyl cellulose, microcrystalline cellulose, talc, silica, dibasic calcium phosphate, and high molecular weight polymers (such as polyethylene glycol).

For parenteral use, a compound of formula 1 can be administered in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable oil or a mixture of liquids, which may contain bacteriostatic agents, antioxidants, preservatives, buffers or other solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Additives of this type include, for example, tartrate, citrate and acetate buffers, ethanol, propylene glycol, polyethylene glycol, complex formers (such as EDTA), antioxidants (such as sodium bisulfite, sodium metabisulfite, and ascorbic acid), high molecular weight polymers (such as liquid polyethylene oxides) for viscosity regulation and polyethylene derivatives of sorbitol anhydrides. Preservatives may also be added if necessary, such as benzoic acid, methyl or propyl paraben, benzalkonium chloride and other quaternary ammonium compounds.



The compounds of this invention may also be administered as solutions for nasal application and may contain in addition to the compounds of this invention suitable buffers, tonicity adjusters, microbial preservatives, antioxidants and viscosity-increasing agents in an aqueous vehicle. Examples of agents used to increase viscosity are polyvinyl alcohol, cellulose derivatives, polyvinylpyrrolidone, polysorbates or glycerin. Microbial preservatives added may include benzalkonium chloride, thimerosal, chloro-butanol or phenylethyl alcohol.

Additionally, the compounds provided by the invention can be administered by suppository.

The compounds of the invention may be administered either alone or in combination with other anti-virals, immunomodulators, antibiotics, anti-infectives, or vaccines. For example the compounds of the invention may be administered in combination with one or more of the known nucleoside analog HIV reverse transcriptase inhibitors, such as AZT, ddI and ddC, other non-nucleoside HIV reverse transcriptase inhibitors, or HIV protease inhibitors.

As stated before, the compounds provided by the invention inhibit the enzymatic activity of HIV-1 RT. Based upon testing of these compounds, as described below, it is known that they inhibit the RNA-dependent DNA polymerase activity of HIV-1 RT. It is known (data not shown) that they also inhibit the DNA-dependent DNA polymerase activity of HIV-1 RT.

Utilizing the Reverse Transcriptase (RT) Assay described below, compounds can be tested for their ability to inhibit the RNA-dependent DNA polymerase activity of HIV-1 RT.

Certain specific compounds described in the Examples which appear below, were so tested.

The results of this testing appear in Table I, below.

## REVERSE TRANSCRIPTASE (RT) ASSAYS

### Assay Theory:

Among the enzymes for which Human Immunodeficiency Virus (HIV-1) encodes is a reverse transcriptase (1), so-named because it transcribes a DNA copy from an RNA template. This activity can be quantitatively measured in a cell-free enzyme assay, which has been previously described (2), and is based upon the observation that reverse transcriptase is able to use a synthetic template [poly r(C) primed with oligo d(G)] to transcribe a radio-labelled, acid-precipitable DNA strand utilizing  $^3\text{H}$ -dGTP as a substrate. The assay described below utilizes the wild type (WT) enzyme, which is the predominant form of the enzyme observed in patients infected with HIV-1. Utilization of mutant RT enzymes (Y181C and Y181L, prepared by site-directed mutagenesis in which the tyrosine residue at codon 181 has been replaced by a cysteine or a leucine residue, respectively) and analogous assay conditions allows compounds to be evaluated for their effectiveness at inhibiting these mutant enzymes.

### Materials:

#### a) Preparation of the wild type enzyme

Reverse transcriptase enzyme from the LAV strain of Human Immunodeficiency Virus (HIV-1) (1) was isolated from the bacterial strain JM109 (3) expressing the DNA clone pBRTprtl+ (2) which is under the control of the lac promotor in the expression vector pIBI21 (4). An overnight culture grown in 2XYT medium (37°C, 225 rpm) (5) supplemented with 100  $\mu\text{g/mL}$  ampicillin for positive selection is inoculated at a 1:40 dilution into M9 medium supplemented with 10  $\mu\text{g/mL}$  thiamine, 0.5% casamino acids, and 50  $\mu\text{g/mL}$  ampicillin (5). The culture is incubated (37°C, 225 rpm) until it reaches an OD<sub>540</sub> of 0.3-0.4. At that time the repressor inhibitor IPTG (isopropyl  $\beta$ -D-thiogalactopyranoside) is added to 0.5mM, and the mixture is incubated for 2 additional hours. Bacteria are pelleted, resuspended in a 50mM Tris, 0.6mM EDTA, 0.375M NaCl buffer and digested by the addition of lysozyme (1mg/mL)

for 30 minutes on ice. The cells are lysed by the addition of 0.2% NP-40 and brought to 1M NaCl.

After removal of the insoluble debris by centrifugation, the protein is precipitated by the addition of 3 volumes of saturated aqueous ammonium sulfate. The enzyme is pelleted, resuspended in RT buffer (50mM Tris pH 7.5, 1mM EDTA, 5mM DTT, 0.1% NP-40, 0.1M NaCl, and 50% glycerol), and stored at -70°C for further use.

b) Composition of 2X concentrated stock reaction mixture

Stock Reagent	2X Mix Concentration
1M Tris pH 7.4	100mM
1M Dithiothrietol	40mM
1M NaCl	120mM
1% Nonidet P-40	0.1%
1M MgCl	4mM
[poly r(C)/oligo d(G)](5:1)	2µg/mL
<sup>3</sup> H-DgTP (81µM)	0.6µM

Assay Procedure:

The 2X concentrated stock reaction mixture is aliquoted and stored at -20°C. The mixture is stable and thawed for use in each assay. This enzyme assay has been adapted to a 96 well microtiter plate system, and has been previously described (6). Tris buffer (50 mM, pH 7.4), vehicle (solvent diluted to match the compound dilution), or compounds in vehicle are dispensed into 96-well microtiter plates (10µL/well; 3 wells/ compound). The HIV-1 RT enzyme is thawed, diluted in 50mM Tris pH 7.4 so that fifteen µL of diluted enzyme contain 0.001 Unit (one unit is that amount of enzyme to transform 1 micromole of substrate per

minute at 25°C), and fifteen µL are dispensed per well. Twenty µL of 0.12-0.5M EDTA are added to the first three wells of the microtiter plate. EDTA chelates the Mg<sup>++</sup> present and prevents reverse transcription. This group serves as background polymerization which is subtracted from all other groups. Twenty-five µL of the 2X reaction mixture are added to all wells and the assay is allowed to incubate at room temperature for 60 minutes. The assay is terminated by precipitating the DNA in each well with 50µL of 10% trichloroacetic acid (TCA) (10% w/v) in sodium pyrophosphate (1% w/v). The microtiter plate is incubated for 15 minutes at 4°C and the precipitate is fixed onto #30 glass fiber paper (Schleicher & Schuell) using a Skatron semi-automatic harvester. The filters are then washed with additional TCA (5%) containing sodium pyrophosphate (1%), rinsed with aqueous ethanol (70%), dried, and transferred to scintillation vials (6). Each vial receives 2 mL of scintillation cocktail and is counted in a Beckman beta counter. The calculation for percent inhibition is as follows:

$$\% \text{ inhibition} = \frac{\text{CPM Mean Test Value} - \text{CPM Mean Control Value} \times 100}{\text{CPM Mean Control Value}}$$


#### References:

1. Benn, S., et al., *Science* 230:949, 1985
2. Farmerie, W.G. et. al., *Science* 236:305, 1987
3. Yanisch-Perron, C., Viera, J., and Messing, J., *Gene* 33:103, 1985
4. International Biotechnologies, Inc., New Haven, CT 06535
5. Maniatis, T, Fritsch, E.F., and J. Sambrook, eds. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1982
6. Spira, T., et. al. *J. Clinical Microbiology*, 25:97, 1987.

TABLE I		
Compound of Example No	Reverse Transcriptase Assay % inhibition (1 $\mu$ M)	
	WT	Y181C
1	68%	34%
2	62%	14%
3	64%	0%
4	68%	9%
5	62%	18%
6	62%	15%
7	75%	21%
8	84%	24%
9	66%	26%
10	91%	46%
11	80%	33%
12	41%	30%
13	80%	56%

Examples.

The following examples further illustrate the present invention and will enable others skilled in the art to understand it more completely. It should be understood, however, that the invention is not limited to the particular examples given below.

Example 15,11-Dihydro-11-ethyl-5-methyl-10-oxo-6H-dipyrido[3,2-b:2'.3'-e]azepin-6-one**N-(2-chloro-3-pyridinyl)-2-methylnicotinamide.**

To a suspension of potassium 2-methylnicotinate (1.82 g) in chloroform (30 mL) was added thionyl chloride (2.0 mL). The mixture was stirred overnight at room temperature under a drying tube. The solvent was evaporated and the residue was taken up in ethyl acetate. 3-Amino-2-chloropyridine (1.28 g) was added followed by diisopropylethylamine (4.0 mL). The reaction mixture was stirred at room temperature under a drying tube for 3 hours. The mixture was diluted with chloroform, washed with water, dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and evaporated. Chromatography of the residue over silica gel (ethyl acetate / hexane) gave N-(2-chloro-3-pyridinyl)-2-methylnicotinamide (1.94 g).

**N-(2-chloro-3-pyridinyl)-N-methyl-2-methylnicotinamide.**


To a stirred solution of N-(2-chloro-3-pyridinyl)-2-methylnicotinamide (1.48 g) in DMSO (20 mL) was added NaH (60% in oil, 0.26 g). After 20 minutes, methyl iodide (0.45 mL) was added, and stirring was continued for 30 minutes. The mixture was diluted with ethyl acetate, washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. Chromatography of the residue over silica gel (ethyl acetate / hexane) gave N-(2-chloro-3-pyridinyl)-N-methyl-2-methylnicotinamide (1.51 g).

**N-(2-chloro-3-pyridinyl)-N-methyl-2-methylnicotinamide N-oxide.**

A mixture of N-(2-chloro-3-pyridinyl)-N-methyl-2-methylnicotinamide (1.86 g) and H<sub>2</sub>O<sub>2</sub> (30%, 5 mL) in acetic acid (10 mL) was heated at 110 °C for 75 minutes. The solvents were evaporated under reduced pressure. Chromatography of the residue over basic alumina (chloroform / ethanol) gave N-(2-chloro-3-pyridinyl)-N-methyl-2-methylnicotinamide N-oxide as an oil which crystallized on trituration with isopropyl ether / ethyl acetate, (1.42 g).


**5,11-dihydro-11-ethyl-5-methyl-10-oxodipyrid[3,2-b:2',3'-e]azepine-6-one.**

To a stirred solution of N-(2-chloro-3-pyridinyl)-N-methyl-2-methylnicotinamide N-oxide (1.11 g) in tetrahydrofuran (15 mL) under nitrogen, cooled on ice, was added dropwise potassium tert-butoxide (1M in tetrahydrofuran, 8.5 mL) over 5 minutes. The mixture was allowed to warm to room temperature, stirred for 30 minutes, and ethyl iodide (0.35 mL) was added. After 90 minutes, the mixture was diluted with chloroform, and washed with water. The aqueous phase was back extracted with chloroform and the combined organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. Chromatography of the residue over basic alumina (methylene chloride / ethanol) gave 5,11-dihydro-11-ethyl-5-methyl-10-oxodipyrid[3,2-b:2',3'-e]azepine-6-one (0.75 g).

Example 25,11-Dihydro-11-ethyl-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one.

To a solution of 5,11-dihydro-11-ethyl-5-methyl-10-oxodipyrido[3,2-b:2',3'-e]azepine-6-one (0.328 g) in chloroform (10 mL) cooled on ice was added phosphorus trichloride (1.0 mL). The mixture was heated under reflux for 10 minutes, cooled, and added to aqueous NaOH (15% solution, 10 mL). Chloroform (50 mL) was added, and the organic phase was separated, dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and evaporated. Chromatography of the residue over silica gel (ethyl acetate / ethanol) gave 5,11-dihydro-11-ethyl-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one (0.209 g).



Example 3.5,11-Dihydro-11-propyl-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one.**5,11-dihydro-11-propyl-5-methyl-10-oxodipyrido[3,2-b:2',3'-e]azepine-6-one**

To a stirred solution of N-(2-chloro-3-pyridinyl)-N-methyl-2-methylnicotinamide N-oxide (0.553 g) in tetrahydrofuran (10 mL) under nitrogen, cooled on ice, was added dropwise sodium bis(trimethylsilyl)amide (1M in tetrahydrofuran, 5 mL). After 5 minutes the mixture was allowed to warm to room temperature, and propyl iodide (0.30 mL) was added. After 3 hours, water was added, the mixture was diluted with chloroform, and the organic phase was separated, washed, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. Chromatography of the residue over basic alumina (chloroform / ethanol) gave 5,11-dihydro-11-propyl-5-methyl-10-oxodipyrido[3,2-b:2',3'-e]azepine-6-one (0.255 g) which was used directly in the next step.


**5,11-dihydro-11-propyl-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one**

To a solution of 5,11-dihydro-11-propyl-5-methyl-10-oxodipyrido[3,2-b:2',3'-e]azepine-6-one (0.255 g) in chloroform (10 mL) cooled on ice was added phosphorus trichloride (0.3 mL). The mixture was heated under reflux for 10 minutes, cooled, and quenched with aqueous NaOH (5% solution). Chloroform (50 mL) was added, and the organic phase was separated, dried

(Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. Chromatography of the residue over silica gel (ethyl acetate / hexane) gave 5,11-dihydro-11-propyl-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one (0.10 g).

#### Example 4.


##### 5,11-Dihydro-11-ethyl-11-methyl-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one



To a solution of 5,11-dihydro-11-ethyl-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one (0.10 g) in DMSO (1 mL) stirred under nitrogen was added potassium tert-butoxide (1M in tetrahydrofuran, 0.5 mL). After 3 minutes, methyl iodide (0.1 mL) was added, and the mixture was stirred for 10 minutes. Ethyl acetate was added, and the mixture was washed with water, dried, filtered, and evaporated. The residue was fractionated by preparative layer chromatography (developer chloroform / ethanol) to give 5,11-dihydro-11-ethyl-11-methyl-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one (0.006 g).

#### Example 5

##### 5,11-Dihydro-11-diethyl-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one




To a stirred solution of N-(2-chloro-3-pyridinyl)-N-methyl-2-methylnicotinamide (0.523 g) in tetrahydrofuran (10 mL) under nitrogen, cooled to -10 °C, was added dropwise sodium

bis(trimethylsilyl)amide (1M in tetrahydrofuran, 5 mL). The mixture was allowed to warm to room temperature, and after 15 minutes ethyl iodide (0.30 mL) was added. After 15 minutes, methanol (1 mL) and ethyl acetate were added. The mixture was washed, dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and evaporated. Chromatography of the residue over silica gel (ethyl acetate / hexane) gave 5,11-dihydro-11-diethyl-5-methyl-10-oxodipyrid[3,2-b:2',3'-e]azepine-6-one (0.098 g).

### Example 6

#### 5,11-Dihydro-11-spirocyclopentyl -5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one



#### **5,11-dihydro-5-methyl-10-oxodipyrid[3,2-b:2',3'-e]azepine-6-one**


To a stirred solution of N-(2-chloro-3-pyridinyl)-N-methyl-2-methylnicotinamide N-oxide (1.02 g) in tetrahydrofuran (20 mL) under argon at room temperature, was added dropwise potassium tert-butoxide (1M in tetrahydrofuran, 7 mL). After 30 minutes, water was added, the mixture was diluted with methylene chloride, and the organic phase was separated, washed, dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and evaporated. Trituration of the residue gave 5,11-dihydro-5-methyl-10-oxodipyrid[3,2-b:2',3'-e]azepine-6-one (0.76 g) which was used directly in the next step.

**5,11-dihydro-5-methyl-10-dipyrido[3,2-b:2',3'-e]azepine-6-one**

To a solution of 5,11-dihydro-5-methyl-10-oxodipyrido[3,2-b:2',3'-e]azepine-6-one (0.199 g) in chloroform (3 mL) was added Lawessons reagent (0.140 g). The mixture was stirred for 30 minutes. Chromatography of the reaction mixture directly over silica gel (ethyl acetate / ethanol) gave 5,11-dihydro-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one (0.172 g).

**5,11-Dihydro-11-spirocyclopentyl-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one.**

To a solution of 5,11-dihydro-5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one (0.069 g) in DMSO (0.6 mL) stirred at room temperature, was added potassium tert-butoxide (1M in tetrahydrofuran, 0.4 mL). After 2 minutes 1,4-diiodobutane (0.11 g) in DMSO (0.3 mL) was added. After 10 minutes, additional potassium tert-butoxide (0.4 mL) was added, and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate, washed with water, dried, filtered, and evaporated. Fractionation of the residue by preparative layer chromatography gave 5,11-Dihydro-11-spirocyclopentyl -5-methyldipyrido[3,2-b:2',3'-e]azepine-6-one (0.019 g).

Example 75,11-Dihydro-11-ethyl-2-methoxy-5-methyl-10-oxodipyrido[3,2-b:2',3'-e]azepine-6-one**N-(2-Bromo-6-methoxy-3-pyridinyl)-2-methylnicotinamide**

To a suspension of potassium 2-methylnicotinate (1.96 g) in chloroform (30 mL) was added thionyl chloride (2.5 mL). The mixture was stirred overnight at room temperature under a drying tube. Diisopropylethylamine (5 mL) was added followed by 3-amino-2-bromo-6-methoxypyridine (2.25 g). After 10 minutes additional diisopropylethylamine (5 mL) was added. After 2 hours the mixture was diluted with chloroform, washed with water, dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and evaporated. Chromatography of the residue over silica gel (chloroform / methanol) gave N-(2-bromo-6-methoxy-3-pyridinyl)-2-methylnicotinamide (2.80 g).

**N-(2-Bromo-6-methoxy-3-pyridinyl)-N-methyl-2-methylnicotinamide N-oxide**

To a stirred solution of N-(2-bromo-6-methoxy-3-pyridinyl)-2-methylnicotinamide (1.61 g) in DMSO (5 mL) was added sodium bis(trimethylsilyl)amide (1M in tetrahydrofuran, 5.5 mL) followed by methyl iodide (0.25 mL). After 15 minutes, the mixture was diluted with ethyl acetate, washed with water, dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and evaporated. The residue was dissolved in acetic acid (5 mL) and 32% peracetic acid (5 mL), and was heated at 100 °C for 1 hour. The solvents were evaporated under reduced pressure. The residue was taken up in chloroform and washed with 5% aqueous sodium hydroxide. The organic phase was dried,


filtered, and evaporated to give N-(2-bromo-6-methoxy-3-pyridinyl)-N-methyl-2-methylnicotinamide N-oxide which crystallized from ethyl acetate, (1.51 g).

**5,11-dihydro-11-ethyl-2-methoxy-5-methyl-10-oxodipyrid[3,2-b:2',3'-e]azepine-6-one**

To a stirred solution of N-(2-bromo-6-methoxy-3-pyridinyl)-N-methyl-2-methylnicotinamide N-oxide (0.655g) in tetrahydrofuran (15 mL) under argon was added dropwise potassium tert-butoxide (1M in tetrahydrofuran, 4 mL). The mixture was stirred at room temperature for 45 minutes, and ethyl iodide (0.2 mL) was added. After 1 hour, the mixture was diluted with chloroform, washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. Chromatography of the residue over silica gel (methylene chloride / ethanol) 5,11-dihydro-11-ethyl-2-methoxy-5-methyl-10-oxodipyrid[3,2-b:2',3'-e]azepine-6-one which crystallized on trituration with ether (0.416 g).


**Example 8**

**5,11-Dihydro-11-ethyl-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one**




**5,11-dihydro-11-ethyl-2-methoxy-5-methyl-10-oxodipyrid[3,2-b:2',3'-e]azepine-6-one.**

A mixture of 5,11-dihydro-11-ethyl-2-methoxy-5-methyl-10-oxodipyrid[3,2-b:2',3'-e]azepine-6-one (0.041 g), and Lawessons reagent (0.030 g) in xylene (1 mL) was heated at 100 °C in a sealed tube for 2 hours. The mixture was fractionated directly by preparative layer chromatography (developer ethyl acetate / hexane 1/1) to give 5,11-dihydro-11-ethyl-2-methoxy-5-methyl-10-dipyrid[3,2-b:2',3'-e]azepine-6-one (0.022 g).

Example 95,11-Dihydro-11-diethyl-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one**5,11-Dihydro-11-diethyl-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one**

To a stirred solution of 5,11-dihydro-11-ethyl-2-methoxy-5-methyl-10-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.032 g) in DMSO (1 mL) was added potassium tert-butoxide (1M in tetrahydrofuran, 0.3 mL). After 5 minutes, ethyl iodide (0.1 mL) was added. After 20 minutes, the mixture was diluted with ethyl acetate, washed with water, dried, filtered, and evaporated. Fractionation of the residue by preparative layer chromatography (developer, ethyl acetate / hexane) gave 5,11-dihydro-11-diethyl-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.024 g).


Example 105,11-Dihydro-11-methylthio-2-methoxy-5-methyl-10-oxodipyrido[3,2-b:2',3'-e]azepine-6-one

To a stirred solution of N-(2-bromo-6-methoxy-3-pyridinyl)-N-methyl-2-methylnicotinamide N-oxide (0.709 g) in tetrahydrofuran (15 mL) was added sodium bis(trimethylsilyl)amide (1M in tetrahydrofuran, 6 mL). After 2 hours, dimethyldisulfide (0.4 mL) was added and the mixture was stirred at room temperature overnight. The mixture was diluted with chloroform, washed with water, dried, filtered, and evaporated. Chromatography of the residue over silica gel

(chloroform/ethanol) gave 5,11-dihydro-11-methylthio-2-methoxy-5-methyl-10-oxodipyrido[3,2-b:2',3'-e]azepine-6-one (0.183 g).

#### Example 11


##### 5,11-Dihydro-11-methylthio-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one



A mixture of 5,11-dihydro-11-methylthio-2-methoxy-5-methyl-10-oxodipyrido[3,2-b:2',3'-e]azepine-6-one (0.067 g) and Lawessons reagent (0.044 g) in xylene (3 mL) was stirred and heated at 90 °C for 20 minutes. The mixture was fractionated directly by preparative layer chromatography (developer, ethyl acetate/hexane) to give 5,11-dihydro-11-methylthio-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.061 g).

#### Example 12

##### 5,11-Dihydro-11-methyl-11-methylthio-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one




To a solution of 5,11-dihydro-11-methylthio-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.031 g) in DMSO (0.5 mL) stirred under argon was added potassium tert-butoxide (1M in tetrahydrofuran, 0.012 mL). After 1 minute, methyl iodide (0.05 mL) was added. After 5 minutes the mixture was diluted with ethyl acetate, washed with water, dried, filtered and evaporated. Fractionation of the residue by preparative layer chromatography



(developer, ethyl acetate/hexane) gave 5,11-dihydro-11-methyl-11-methylthio-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.029).

### Example 13

#### 5,11-Dihydro-11-ethyl-2-(4-pyrazolyl)-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one



#### **5,11-Dihydro-11-ethyl-2-trifluoromethanesulfonyloxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one**

A solution of 5,11-dihydro-11-ethyl-2-methoxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.181 g) in acetic acid (1 mL) and 48% HBr in acetic acid (1 mL) was heated at 110 °C for 10 minutes. The mixture was cooled, neutralized with saturated sodium bicarbonate, and extracted with chloroform. The organic phase was dried, filtered and evaporated to give 5,11-dihydro-11-ethyl-2-hydroxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.176 g) which was used directly in the next reaction.

To a solution of 5,11-dihydro-11-ethyl-2-hydroxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.176 g) in chloroform (10 mL) cooled on ice was added triethylamine (0.25 mL) followed by triflic anhydride (0.2 mL). After 10 minutes, the mixture was diluted with ethyl acetate, washed with water, dried, filtered, and evaporated. Chromatography of the residue over silica

gel (ethyl acetate/hexane) gave 5,11-dihydro-11-ethyl-2-trifluoromethanesulfonyloxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.165 g).

**5,11-Dihydro-11-ethyl-2-(4-pyrazolyl)-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one**

A mixture of 5,11-dihydro-11-ethyl-2-trifluoromethanesulfonyloxy-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.084 g), 4-tributylstannylpyrazole (0.096 g), lithium chloride (0.052 g) and  $\text{Pd}(\text{Ph}_3\text{P})_2\text{Cl}_2$  (0.009 g) in dimethylformamide (1 mL) was heated at 120 °C in a sealed tube 16 hours. The mixture was diluted with ethyl acetate, washed with water, dried, filtered and evaporated. Chromatography of the residue over silica gel (ethyl acetate/hexane) gave 5,11-dihydro-11-ethyl-2-(4-pyrazolyl)-5-methyl-dipyrido[3,2-b:2',3'-e]azepine-6-one (0.010 g).

**Example A**

**Capsules or Tablets**

A-1		A-2	
Ingredients	Quantity	Ingredients	Quantity
Compound of Ex. 12	250 mg	Compound of Ex. 12	50 mg
Starch	160 mg	Dicalcium Phosphate	160 mg
Microcrys. Cellulose	90 mg	Microcrys. Cellulose	90 mg
Na Starch Glycolate	10 mg	Stearic acid	5 mg
Magnesium Stearate	2 mg	Sodium Starch Glycolate	10 mg
Fumed colloidal silica	1 mg	Fumed colloidal silica	1 mg

The compound of Example 13 is blended into a powder mixture with the premixed excipient materials as identified above with the exception of the lubricant. The lubricant is then blended in and the resulting blend compressed into tablets or filled into hard gelatin capsules.

**EXAMPLE B****Parenteral Solutions**

Ingredients	Quantity
Compound of Example 12	500mg
Tartaric acid	1.5g
Benzyl Alcohol	0.1% by weight
Water for injection	q.s. to 100mL

The excipient materials are mixed with the water and thereafter the compound of Example 13 is added. Mixing is continued until the solution is clear. The pH of this solution is adjusted to 3.0 and is then filtered into the appropriate vials or ampoules and sterilized by autoclaving.


**EXAMPLE C****Nasal Solutions**

Ingredients	Quantity
Compound of Example 12	100mg
Citric acid	1.92g
Benzalkonium chloride	0.025% by weight
EDTA	0.1 % by weight
Polyvinylalcohol	10% by weight
Water	q.s. to 100mL

The excipient materials are mixed with the water and thereafter the compound of Example 13 is added and mixing is continued until the solution is clear. The pH of this solution is adjusted to 4.0 and is then filtered into the appropriate vials or ampoules.

What Is Claimed Is:

1. A compound of the formula 1



wherein:

X is an oxygen atom or nothing;

R<sup>1</sup> is hydrogen, alkyl of 1 to 4 carbon atoms, fluoroalkyl of 1 to 4 carbon atoms and 1 to 3 fluorine atoms, cycloalkyl of 3 to 6 carbon atoms, alkylthio of 1 to 2 carbon atoms, alkyloxy of 1 to 2 carbon atoms, oxetanyl, thietanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, alkenylmethyl or alkynylmethyl of 3 to 4 carbon atoms, alkyloxyalkyl or alkylthioalkyl of 2 to 3 carbon atoms, alkanoyl or alkyl(thiocarbonyl) of 2 to 5 carbon atoms, or cyanoalkyl of 2 to 3 carbon atoms;

R<sup>2</sup> is hydrogen, methyl or ethyl;

R<sup>3</sup> is a hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 6 carbon atoms, trihalomethyl, hydroxyalkyl of 1 to 6 carbon atoms, alkyloxy or alkylthio of 2 to 6 carbon atoms, alkyloxyalkyl or alkylthioalkyl of 2 to 6 carbon atoms, pyrrolidinyl, pyrrolinyl, piperidinyl, mono- or di-alkylamino wherein each alkyl moiety contains 1 to 3 carbon atoms, halogen, cyano, nitro, or carboxyl, aryl (wherein aryl is phenyl, pyridinyl, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,

thiazolyl or isothiazolyl) which is either unsubstituted or substituted by hydroxyl, amino, halogen, alkyl or alkyloxy of 1 to 3 carbon atoms.

2. A compound of formula 1, as set forth in claim 1,

wherein:

X is nothing;

R<sup>1</sup> is hydrogen, alkyl of 1 to 3 carbon atoms, cycloalkyl of 3 to 4 carbon atoms, alkylthio of 1 to 2 carbon atoms;

R<sup>2</sup> is hydrogen, methyl or ethyl;

R<sup>3</sup> is a hydrogen atom, methyl, trihalomethyl, alkyloxy or alkylthio of 1 to 2 carbon atoms, pyrrolidinyl, pyrrolinyl, piperidinyl, di-alkylamino wherein each alkyl moiety contains 1 to 2 carbon atoms, halogen, cyano, aryl (wherein aryl is phenyl, pyridinyl, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl or isothiazolyl) which is either unsubstituted or substituted by hydroxyl, amino, halogen, alkyl or alkyloxy of 1 to 3 carbon atoms.

3. 5,11 dihydro-11-ethyl-2-methoxy-5-methyl-dipyrido[3,2-*b*:2',3'-*e*]azepine-6-one;

5,11-dihydro-11-ethyl-2-(4-pyrazolyl)-5-methyl-dipyrido[3,2-*b*:2',3'-*e*]azepine-6-one,

and the pharmaceutically acceptable salts thereof.

4. A method for inhibiting HIV-1 replication in a human host infected by HIV-1, which comprises administering to such host an amount of a compound of formula 1, as set forth in claims 1, 2, or 3, or a pharmaceutically acceptable salt thereof, which is sufficient to inhibit HIV-1 replication.
5. A method for treating HIV-1 infection which comprises administering, to a human being exposed to or infected by HIV-1, a therapeutically effective amount of a compound of formula 1, as set forth in claims 1, 2, or 3, or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition suitable for treating HIV-1 infection which comprises a therapeutically effective amount of a compound of formula 1, as set forth in claims 1, 2, or 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/16707

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 31/55; C07D 487/12

US CL : 514/215; 540/521

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/215; 540/521

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KELLY et al., Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. 5. 4-Substituted and 2,4-Disubstituted Analogs of Nevirapine, Journal of Medicinal Chemistry, November 24, 1995, Vol. 38, No. 24, pages 4839-4847, especially page 4842.	1-6

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 OCTOBER 1998

Date of mailing of the international search report

30 OCT 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MUKUND SHAH

Telephone No. (703) 308-1235

